

Siddiqui, KhanDOB: **07/02/1973****Patient Report**

Patient ID: **PAT-KDGPQ5EXQ4HL**
 Specimen ID: **092-139-4127-0**

Age: **51**Sex: **Male**Account Number: **11009950**Ordering Physician: **S CLARK**Date Collected: **04/02/2025**Date Received: **04/02/2025**Date Reported: **04/07/2025**Fasting: **No**

Ordered Items: **NMR LipoProfile+Lipids+Graph; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Iron and TIBC; Apo A1 + B + Ratio; Testosterone,Free and Total; Vitamin B12 and Folate; Hemoglobin A1c; TSH; Thyroxine (T4) Free, Direct; Homocyst(e)ine; Methylmalonic Acid, Serum; C-Reactive Protein, Cardiac; Cortisol; Vitamin D, 25-Hydroxy; Uric Acid; Phosphorus; Sedimentation Rate-Westergren; Bilirubin, Direct; Magnesium; Triiodothyronine (T3), Free; Sex Horm Binding Glob, Serum; Ferritin; Insulin**

Date Collected: **04/02/2025****NMR LipoProfile+Lipids+Graph**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LDL Particle Number⁰¹				
LDL-P ^{A,01}	559	756	10/30/2024	nmol/L
		Low	< 1000	
		Moderate	1000 - 1299	
		Borderline-High	1300 - 1599	
		High	1600 - 2000	
		Very High	> 2000	
Lipids⁰¹				
LDL-C (NIH Calc) ⁰¹	54	70	10/30/2024	mg/dL
		Optimal	< 100	
		Above optimal	100 - 129	
		Borderline	130 - 159	
		High	160 - 189	
		Very high	> 189	
HDL-C ^{A,01}	41	37	10/30/2024	mg/dL
Triglycerides ^{A,01}	78	91	10/30/2024	mg/dL
Cholesterol, Total ^{A,01}	111	125	10/30/2024	mg/dL
LDL and HDL Particles⁰¹				
▼ HDL-P (Total) ^{A,01}	28.5	Low	10/30/2024	umol/L
Small LDL-P ^{A,01}	324	328	10/30/2024	nmol/L
▼ LDL Size ^{A,01}	20.4	Low	10/30/2024	nm

**** INTERPRETATIVE INFORMATION******PARTICLE CONCENTRATION AND SIZE**

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES Percentile in Reference Population

HDL-P (total) High 75th 50th 25th Low
>34.9 34.9 30.5 26.7 <26.7Small LDL-P Low 25th 50th 75th High
<117 117 527 839 >839LDL Size <-Large (Pattern A)-> <-Small (Pattern B)->
23.0 20.6 20.5 19.0**Comment:⁰¹**

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score⁰¹LP-IR Score^{A,01}

27

37

10/30/2024

<=45

INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->

labcorpDate Created and Stored 04/07/25 2113 ET **Final Report** Page 1 of 7

Siddiqui, KhanPatient ID: **PAT-KDGPQ5EXQ4HL**
Specimen ID: **092-139-4127-0**DOB: **07/02/1973**Age: **51**
Sex: **Male****Patient Report**Account Number: **11009950**
Ordering Physician: **S CLARK**Date Collected: **04/02/2025****NMR LipoProfile+Lipids+Graph (Cont.)**

Percentile in Reference Population

Insulin Resistance Score

LP-IR Score	Low	25th	50th	75th	High
<27	27	45	63	>63	

Comment:⁰¹

LP-IR Score is inaccurate if patient is non-fasting.
 The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

PDF⁰¹

.

10/30/2024

Historical Reporting⁰¹

Comment:

Collection Date	LDL-P	LDL-C
04/02/2025	559	54
10/30/2024	756	70

CBC With Differential/Platelet

Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval
WBC ⁰²	6.2		6.2	10/30/2024	x10E3/uL	3.4-10.8
RBC ⁰²	5.60		5.16	10/30/2024	x10E6/uL	4.14-5.80
Hemoglobin ⁰²	14.2		13.3	10/30/2024	g/dL	13.0-17.7
Hematocrit ⁰²	46.6		42.5	10/30/2024	%	37.5-51.0
MCV ⁰²	83		82	10/30/2024	fL	79-97
▼ MCH ⁰²	25.4	Low	25.8	10/30/2024	pg	26.6-33.0
▼ MCHC ⁰²	30.5	Low	31.3	10/30/2024	g/dL	31.5-35.7
RDW ⁰²	15.0		14.6	10/30/2024	%	11.6-15.4
Platelets ⁰²	252		247	10/30/2024	x10E3/uL	150-450
Neutrophils ⁰²	63		67	10/30/2024	%	Not Estab.
Lymphs ⁰²	23		21	10/30/2024	%	Not Estab.
Monocytes ⁰²	9		7	10/30/2024	%	Not Estab.

labcorpDate Created and Stored 04/07/25 2113 ET **Final Report** Page 2 of 7

Siddiqui, KhanDOB: **07/02/1973****Patient Report**

Patient ID: **PAT-KDGPQ5EXQ4HL**
 Specimen ID: **092-139-4127-0**

Age: **51**
 Sex: **Male**

Account Number: **11009950**
 Ordering Physician: **S CLARK**

Date Collected: **04/02/2025****CBC With Differential/Platelet (Cont.)**

Eos ⁰²	4	4	10/30/2024	%	Not Estab.
Basos ⁰²	1	0	10/30/2024	%	Not Estab.
Neutrophils (Absolute) ⁰²	4.0	4.2	10/30/2024	x10E3/uL	1.4-7.0
Lymphs (Absolute) ⁰²	1.4	1.3	10/30/2024	x10E3/uL	0.7-3.1
Monocytes(Absolute) ⁰²	0.6	0.5	10/30/2024	x10E3/uL	0.1-0.9
Eos (Absolute) ⁰²	0.2	0.2	10/30/2024	x10E3/uL	0.0-0.4
Baso (Absolute) ⁰²	0.0	0.0	10/30/2024	x10E3/uL	0.0-0.2
Immature Granulocytes ⁰²	0	1	10/30/2024	%	Not Estab.
Immature Grans (Abs) ⁰²	0.0	0.0	10/30/2024	x10E3/uL	0.0-0.1

Comp. Metabolic Panel (14)

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval	
Glucose ⁰²	85		90	10/30/2024	mg/dL	70-99
BUN ⁰²	23		20	10/30/2024	mg/dL	6-24
Creatinine ⁰²	0.95		0.82	10/30/2024	mg/dL	0.76-1.27
eGFR	97		106	10/30/2024	mL/min/1.73	>59
▲ BUN/Creatinine Ratio	24	High	24	10/30/2024		9-20
Sodium ⁰²	141		141	10/30/2024	mmol/L	134-144
Potassium ⁰²	3.9		4.4	10/30/2024	mmol/L	3.5-5.2
Chloride ⁰²	102		107	10/30/2024	mmol/L	96-106
Carbon Dioxide, Total ⁰²	22		20	10/30/2024	mmol/L	20-29
Calcium ⁰²	9.1		9.1	10/30/2024	mg/dL	8.7-10.2
Protein, Total ⁰²	6.9		6.5	10/30/2024	g/dL	6.0-8.5
Albumin ⁰²	4.5		4.4	10/30/2024	g/dL	3.8-4.9
Globulin, Total	2.4		2.1	10/30/2024	g/dL	1.5-4.5
Bilirubin, Total ⁰²	0.6		0.4	10/30/2024	mg/dL	0.0-1.2
Alkaline Phosphatase ⁰²	68		67	10/30/2024	IU/L	44-121
AST (SGOT) ⁰²	19		18	10/30/2024	IU/L	0-40
ALT (SGPT) ⁰²	18		21	10/30/2024	IU/L	0-44

Iron and TIBC

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval	
Iron Bind.Cap.(TIBC)	344		335	10/30/2024	ug/dL	250-450
UIBC ⁰²	301		299	10/30/2024	ug/dL	111-343
Iron ⁰²	43		36	10/30/2024	ug/dL	38-169
▼ Iron Saturation	13	Low	11	10/30/2024	%	15-55

Apo A1 + B + Ratio

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval	
Apolipoprotein A-1 ⁰¹	126		112	10/30/2024	mg/dL	101-178
Apolipoprotein B ⁰¹	53		59	10/30/2024	mg/dL	<90
				Desirable	< 90	
				Borderline High	90 - 99	
				High	100 - 130	

labcorpDate Created and Stored 04/07/25 2113 ET **Final Report** Page 3 of 7

Siddiqui, KhanPatient ID: **PAT-KDGPQ5EXQ4HL**
Specimen ID: **092-139-4127-0**DOB: **07/02/1973**Age: **51**
Sex: **Male****Patient Report**Account Number: **11009950**
Ordering Physician: **S CLARK**Date Collected: **04/02/2025****Apo A1 + B + Ratio (Cont.)**

		Very High	>130	
	ASCVD RISK CATEGORY		THERAPEUTIC TARGET APO B (mg/dL)	
	Very High Risk	<80 (if extreme risk <70)		
	High Risk	<90		
	Moderate Risk	<90		
Apolipo. B/A-1 Ratio	0.4	0.5	10/30/2024 ratio Apolipoprotein B/A-1 Ratio Male Female Avg.Risk 0.7 0.6 2X Avg.Risk 0.9 0.9 3X Avg.Risk 1.0 1.0	0.0-0.7

Testosterone,Free and Total

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Testosterone ⁰²	439	268 10/30/2024	ng/dL	264-916
	Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017, 102;1161-1173. PMID: 28324103.			

▼ Free Testosterone(Direct)⁰¹**5.2****Low****2.4**

10/30/2024

pg/mL

7.2-24.0

Vitamin B12 and Folate

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin B12 ⁰²	774	975 10/30/2024	pg/mL	232-1245
Folate (Folic Acid), Serum ⁰²	15.2	6.6 10/30/2024	ng/mL	>3.0

Note:⁰²

A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.

Hemoglobin A1c

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Hemoglobin A1c ⁰²	5.5	5.6 10/30/2024	%	4.8-5.6

Please Note:⁰²

Prediabetes: 5.7 - 6.4

Diabetes: >6.4

Glycemic control for adults with diabetes: <7.0

TSH

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH ⁰²	1.860	1.360 10/30/2024	uIU/mL	0.450-4.500

Thyroxine (T4) Free, Direct

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
T4,Free(Direct) ⁰²	1.46	1.37 10/30/2024	ng/dL	0.82-1.77

labcorpDate Created and Stored 04/07/25 2113 ET **Final Report** Page 4 of 7

Siddiqui, KhanPatient ID: **PAT-KDGPQ5EXQ4HL**
Specimen ID: **092-139-4127-0**DOB: **07/02/1973**Age: **51**
Sex: **Male****Patient Report**Account Number: **11009950**
Ordering Physician: **S CLARK**Date Collected: **04/02/2025****Homocyst(e)ine**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Homocyst(e)ine ⁰²	8.7	9.5 10/30/2024	umol/L	0.0-14.5

Methylmalonic Acid, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Methylmalonic Acid, Serum ^{A, 01}	108	111 10/30/2024	nmol/L	0-378

C-Reactive Protein, Cardiac

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
C-Reactive Protein, Cardiac ⁰²	2.10		mg/L	0.00-3.00
Relative Risk for Future Cardiovascular Event				
Low <1.00				
Average 1.00 - 3.00				
High >3.00				

Cortisol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Cortisol ⁰²	13.1	10.3 10/30/2024	ug/dL	6.2-19.4
Please Note: The reference interval and flagging for this test is for an AM collection. If this is a PM collection please use: Cortisol PM: 2.3-11.9				

Vitamin D, 25-Hydroxy

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin D, 25-Hydroxy ⁰²	71.6	18.8 10/30/2024	ng/mL	30.0-100.0
<p>Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).</p> <p>1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.</p> <p>2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.</p>				

Uric Acid

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Uric Acid ⁰²	5.7	4.6 10/30/2024	mg/dL	3.8-8.4
Therapeutic target for gout patients: <6.0				

Phosphorus

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Phosphorus ⁰²	3.1	3.3 10/30/2024	mg/dL	2.8-4.1

labcorpDate Created and Stored 04/07/25 2113 ET **Final Report** Page 5 of 7

Siddiqui, KhanPatient ID: **PAT-KDGPQ5EXQ4HL**
Specimen ID: **092-139-4127-0**DOB: **07/02/1973**Age: **51**
Sex: **Male****Patient Report**Account Number: **11009950**
Ordering Physician: **S CLARK**Date Collected: **04/02/2025****Sedimentation Rate-Westergren**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Sedimentation Rate-Westergren ⁰²	14	9	10/30/2024	mm/hr

Bilirubin, Direct

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Bilirubin, Direct ⁰²	0.20	0.14	10/30/2024	mg/dL

Magnesium

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ Magnesium ⁰²	2.5	High	2.2	10/30/2024

Triiodothyronine (T3), Free

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Triiodothyronine (T3), Free ⁰²	3.1	2.4	10/30/2024	pg/mL

Sex Horm Binding Glob, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Sex Horm Binding Glob, Serum ⁰²	44.8	27.3	10/30/2024	nmol/L

Ferritin

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Ferritin ⁰²	35	28	10/30/2024	ng/mL

Insulin

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Insulin ⁰²	14.6	21.1	10/30/2024	uIU/mL

Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend

▲ Out of Reference Range ■ Critical or Alert

Comments

A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs

01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD

02: CB - Labcorp Dublin, 6370 Wilcox Road, Dublin, OH 43016-1269 Dir: Vincent Ricchiuti, PhD

For inquiries, the physician may contact Branch: 800-598-3345 Lab: 800-282-7300

Patient ID: **PAT-KDGPQ5EXQ4HL**Age: **51**Account Number: **11009950**Specimen ID: **092-139-4127-0**Sex: **Male**Ordering Physician: **S CLARK****Patient Details**

Siddiqui, Khan
630 N MADISON ST, HINSDALE, IL,
605212834

Phone: **443-847-5106**Date of Birth: **07/02/1973**Age: **51**Sex: **Male**Patient ID: **PAT-KDGPQ5EXQ4HL**Alternate Patient ID: **PAT-KDGPQ5EXQ4HL****Physician Details**

S CLARK
Clark Family Medicine
1246 Yellowstone Ave Ste A2, Pocatello, ID,
83201

Phone: **208-595-6976**
Account Number: **11009950**
Physician ID: **CLARK,S**
NPI: **1093078578**

Specimen Details

Specimen ID: **092-139-4127-0**
Control ID: **1683191**
Alternate Control Number:
Date Collected: **04/02/2025 0000 Local**
Date Received: **04/02/2025 0000 ET**
Date Entered: **04/02/2025 2323 ET**
Date Reported: **04/07/2025 2106 ET**

Specimen Number 092-139-4127-0	Patient ID PAT-KDGPQ5EXQ4HL	Account Number 11009950	Account Phone (208) 595-6976	Account Fax (208) 595-6976
Patient Last Name SIDDIQUI	Patient First Name KHAN		Account Address Clark Family Medicine 1246 Yellowstone Ave Ste A2 Pocatello, ID 83201	
Age 51	Date of Birth 07/02/1973	Sex M	Fasting NO	
Control Number 1683191		NPI 1093078578		
Date Collected 04/02/2025	Date Entered 04/02/2025	Date and Time Reported 04/03/2025 06:45 PM ET	Physician ID & Name CLARK,S - CLARK, S	Page Number 1 of 2

❖ NMR LipoProfile ® test
Reference Interval¹

Percentile ¹	20th	50th	80th	95th
nmol/L	Low	Moderate	Borderline High	High Very High

LDL-P (LDL Particle Number)	559	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000
---------------------------------------	------------	--------	-------------	-------------	-------------	--------


1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ Lipids

mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
-------	---------	-----------------------	-----------------	------	-----------

LDL-C (calculated)	54	< 100	100 - 129	130 - 159	160 - 189	≥ 190
------------------------------	-----------	-------	-----------	-----------	-----------	-------

HDL-C	mg/dL 41	mg/dL Triglycerides Desirable ≥ 40	mg/dL Total Cholesterol Desirable < 200
--------------	-------------	--	---

Historical Reporting


* This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

Issued or Pending PATENTS The NMR LipoProfile ® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number 34D0655059





1447 York Court
Burlington, NC 27215
800-788-9223

Medical Director: Sanjai Nagendra, MD

Specimen Number 092-139-4127-0	Patient ID PAT-KDGPQ5EXQ4HL	Account Number 11009950	Account Phone (208) 595-6976	Account Fax (208) 595-6976		
Patient Last Name SIDDIQUI	Patient First Name KHAN	Account Address Clark Family Medicine 1246 Yellowstone Ave Ste A2 Pocatello, ID 83201				
Age 51	Date of Birth 07/02/1973				Sex M	Fasting NO
Control Number 1683191	NPI 1093078578					
Date Collected 04/02/2025	Date Entered 04/02/2025	Date and Time Reported 04/03/2025 06:45 PM ET	Physician ID & Name CLARK,S - CLARK, S	Page Number 2 of 2		

PARTICLE CONCENTRATION AND SIZE



Clinician Notes

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

^① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al.. Metab Syndr Relat Disord 2014; 12:422-9.

^③ Mackey RH et al.. Diab Care 2015; 38:628-36.